Somewhat Negative Media Coverage Somewhat Unlikely to Affect Aeglea BioTherapeutics (AGLE) Stock Price
News stories about Aeglea BioTherapeutics (NASDAQ:AGLE) have been trending somewhat negative this week, according to Accern. The research firm scores the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aeglea BioTherapeutics earned a media sentiment score of -0.02 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 47.9114083470846 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Shares of Aeglea BioTherapeutics (NASDAQ:AGLE) traded down 2.37% during midday trading on Tuesday, reaching $4.53. The company’s stock had a trading volume of 15,103 shares. Aeglea BioTherapeutics has a one year low of $2.81 and a one year high of $10.34. The firm’s market cap is $74.53 million. The stock’s 50 day moving average price is $3.60 and its 200 day moving average price is $5.00.
A number of equities research analysts have issued reports on the company. Zacks Investment Research upgraded Aeglea BioTherapeutics from a “hold” rating to a “buy” rating and set a $3.75 price objective on the stock in a research report on Thursday, August 3rd. ValuEngine downgraded Aeglea BioTherapeutics from a “sell” rating to a “strong sell” rating in a research report on Thursday, July 6th. Finally, TheStreet downgraded Aeglea BioTherapeutics from a “c-” rating to a “d+” rating in a research report on Friday, May 26th.
Aeglea BioTherapeutics Company Profile
Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.
Receive News & Stock Ratings for Aeglea BioTherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea BioTherapeutics Inc. and related stocks with our FREE daily email newsletter.